Skip to main content

Table 2 Bacterial isolates and susceptibility characteristics to meropenem in clinically evaluable population

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

  Number n (%) MIC (mg/l)
Pathogen1 Infusion group
n = 106
Bolus group
n = 108
P Infusion group
n = 106
Bolus group
n = 108
P
None cultured 10 (9.4%) 6 (5.6%) 0.310 n/a n/a n/a
Acinetobacter spp. 8 (7.5%) 12 (11.1%) 0.482 2.000 (1.000 to 2.000) 1.500 (1.500 to 2.000) 0.635
Citrobacter spp. 3 (2.8%) 4 (3.7%) 1.000 0.190 (0.092 to 0.422) 0.125 (0.040 to 0.470) 0.724
Enterobacter spp. 3 (2.8%) 7 (6.5%) 0.332 0.190 (0.093 to 0.331) 0.060 (0.053 to 0.090) 0.170
Escherichia coli 6 (5.7%) 9 (8.3%) 0.594 0.090 (0.090 to 0.120) 0.120 (0.072 to 0.380) 0.260
Klebsiella spp. 63 (59.4%) 50 (46.3%) 0.057 0.120 (0.090 to 0.130) 0.090 (0.060 to 0.130) 0.205
Morganella morganii 3 (2.8%) 5 (4.6%) 0.721 0.250 (0.250 to 0.542) 0.320 (0.250 to 0.535) 0.760
Pseudomonas aeruginosa 4 (3.8%) 6 (5.6%) 0.748 2.000 (1.750 to 2.000) 1.750 (1.000 to 2.000) 0.363
Serratia marcescens 4 (3.8%) 6 (5.6%) 0.748 0.110 (0.094 to 0.222) 0.125 (0.094 to 0.190) 0.830
Stenotrophomonas maltophilia 2 (1.9%) 3 (2.8%) 1,000 2.000 (2.000 to 2.000) 2.000 (1.625 to 2.000) 0.519
MIC of all microorganisms     0.125 (0.090 to 0.640) 0.130 (0.090 to 0,350) 0.970
  1. Values are presented as absolute (percentage) or median (interquartile range).
  2. 1 Isolates do not include all pathogens, but those treated with meropenem; MIC, minimum inhibitory concentration; n/a, not applicable